Literature DB >> 12637079

Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase.

Mehrdad Mousavi-Jazi1, Lottie Schloss, Britta Wahren, Maria Brytting.   

Abstract

BACKGROUND: In vitro selection of viruses with decreased drug susceptibility is a useful tool for mapping drug resistance-associated alterations, evaluating cross-resistance profiles, and elucidating molecular mechanisms of antiviral activity.
OBJECTIVES: To provide data on mechanisms of selective drug action and features of drug resistance that may be clinically important. STUDY
DESIGN: Foscarnet (PFA) and ganciclovir (GCV) were used to induce mutants of the human cytomegalovirus (HCMV) Towne strain.
RESULTS: Three new mutations, selected in the presence of PFA, were identified with single base substitutions resulting in T419M, Q578H, and L773V in conserved regions of the HCMV DNA polymerase. None of these mutations have been reported previously. These mutations conferred resistance to PFA but did not change the susceptibility to GCV. A mutant was selected in the presence of GCV. This GCV-selected mutant had no mutation in the UL54 but had an amino acid alteration at codon M460V of UL97, which conferred resistance to GCV. All the mutants had the same growth phenotype as the parental laboratory strain Towne.
CONCLUSIONS: We have determined three novel alterations in HCMV DNA polymerase inducing reduced susceptibility to PFA. None of these alterations changed the growth phenotype of the parental virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637079     DOI: 10.1016/s1386-6532(02)00046-x

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  8 in total

1.  Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.

Authors:  Sunwen Chou; Ronald J Ercolani; Malaya K Sahoo; Martina I Lefterova; Lynne M Strasfeld; Benjamin A Pinsky
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

2.  Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients.

Authors:  Seong Jin Kim; Yao-Ting Huang; Julia Foldi; Yeon Joo Lee; Molly Maloy; Sergio A Giralt; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Transpl Infect Dis       Date:  2018-04-10       Impact factor: 2.228

3.  How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.

Authors:  Firas El Chaer; Dimpy P Shah; Roy F Chemaly
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

4.  Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.

Authors:  Sunwen Chou
Journal:  J Clin Virol       Date:  2011-02-03       Impact factor: 3.168

Review 5.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.

Authors:  Sunwen Chou
Journal:  Antiviral Res       Date:  2016-12-08       Impact factor: 5.970

7.  A point mutation within conserved region VI of herpes simplex virus type 1 DNA polymerase confers altered drug sensitivity and enhances replication fidelity.

Authors:  Ying T Hwang; Harmon J Zuccola; Qiaosheng Lu; Charles B C Hwang
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Implementation and Evaluation of a Fully Automated Multiplex Real-Time PCR Assay on the BD Max Platform to Detect and Differentiate Herpesviridae from Cerebrospinal Fluids.

Authors:  Thomas Köller; Daniel Kurze; Mirjam Lange; Martin Scherdin; Andreas Podbielski; Philipp Warnke
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.